- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07493577
Indukovaná suprese aktivity trombocytů při léčbě aneurysmatického subarachnoidálního krvácení-2 (iSPASM-2) (iSPASM-2)
Indukovaná suprese aktivity trombocytů v managementu aneurysmatického subarachnoidálního krvácení-2
An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
This is an exploratory, two-center, randomized, double-blinded study. The primary objective is to determine the maximum tolerated dosage (MTD) of tirofiban in the context of patients with aSAH status post-endovascular coiling. The dosage regimen of tirofiban will be 0.10µg/kg/min (actual weight) within 48 hours of aneurysm securing and within 72 hours of ictus.
The study will involve a dose escalation stage and a cohort expansion stage. During the dosage-escalation stage, the intervention doses include continuous intravenous (IV) tirofiban or IV placebo for 1 day, 3 days, 5 days, or 7 days. Dose-escalation will follow the time-to-event Bayesian Optimal Intervention (TITE-BOIN) design. Unlike the majority of existing phase I designs, which require suspending the accrual after treating each cohort of patients, the TITE-BOIN design allows for real-time dose assignment decisions for new patients while the toxicity data are still pending for some patients under treatment. This shortens the trial duration and reduces the logistical difficulties caused by frequent suspensions of accrual. For parallel comparison under real-world conditions, patients will be randomly assigned to tirofiban and placebo in a 2:1 ratio in the dose escalation stage. The data from the placebo patients will not be analyzed to inform dose escalation but included in the final analysis upon study completion. Upon the completion of the dose escalation stage, the MTD will be selected using isotonic regression. MTD will be selected as the dosage for which the isotonic estimate of the toxicity rate is closest to the target dosage-limiting toxicity rate (30%). If there is a tie, we will select the higher dosage level when the isotonic estimate is lower than the target toxicity rate, and we will select the lower dosage level when the isotonic estimate is greater than or equal to the target toxicity rate.
During the cohort expansion stage, patients will be randomized to tirofiban at MTD and placebo at the corresponding dosage level to achieve balanced sample sizes (30 tirofiban at MTD and 30 placebo for any infusion duration, combined from both phases) across the two groups. The analysis of the exploratory endpoints will be performed on the tirofiban patients at MTD and placebo patients with any infusion duration.
An interim pharmacokinetic (PK) analysis will be performed after 10 evaluable patients are treated with tirofiban to determine possible dose modification. At the completion of the study, PK and pharmacodynamic (PD) analysis will be conducted using all evaluable patients treated with tirofiban to determine whether augmented renal clearance in aSAH interacts with the pharmacokinetics and pharmacodynamics of tirofiban.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Studijní kontakt
- Jméno: Beth Perry
- Telefonní číslo: 919-681-2695
- E-mail: beth.perry@duke.edu
Studijní záloha kontaktů
- Jméno: Hazani Benitez-Rosas
- Telefonní číslo: 919-681-4974
- E-mail: hazani.benitez-rosas@duke.edu
Studijní místa
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Duke University Health System
-
Kontakt:
- Hazani Benitez-Rosas, AS
- Telefonní číslo: 919-681-4974
- E-mail: hazani.benitez-rosas@duke.edu
-
Kontakt:
- Beth A Perry, RN
- Telefonní číslo: 919-681-2695
- E-mail: beth.perry@duke.edu
-
Vrchní vyšetřovatel:
- Emad Hasan, MD
-
Vrchní vyšetřovatel:
- Brian Mac Grory, MD
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- University of Texas Health Sciences Center
-
Kontakt:
- Sprios Blackburn, MD
- Telefonní číslo: 713-486-8000
- E-mail: Spiros.Blackburn@uth.tmc.edu
-
Vrchní vyšetřovatel:
- Spiros Blackburn, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion:
- Age 18-85
- Baseline Modified Rankin Scale (mRS) 0-3 (pre-SAH)
- SAH attributed to ruptured cerebral aneurysm
- Admission Computed Tomography (CT) scan shows Modified Fisher grade 1-4 due to aSAH primarily in the supratentorial space
- World Federation of Neurosurgical Societies (WFNS) scale grade ≤4 at randomization
- Onset of symptoms of aSAH (ictus) occurred <72 hours prior to presentation
- If External Ventricular Drain (EVD) placed, placement is ≥12 hours prior to enrollment
- All aneurysm(s) suspected to be responsible for the hemorrhage must be secured via Endovascular Coil Embolization with a post-embolization Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) prior to enrollment
- Participant can be randomized within 48 hours of aneurysm treatment
- Participant or participant's legally-authorized representative (LAR) has provided documented informed consent
Exclusion:
-
Angio-negative SAH, defined as a SAH with a digital subtraction angiogram that does not show an intracranial aneurysm
-
Surgical clipping prior of the ruptured aneurysm or any non-ruptured aneurysm on the same admission to enrollment
-
Remaining untreated aneurysm(s) that could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern
-
Uncontrollable hypertension (>180 systolic and/or >110 diastolic) that is not correctable prior to enrollment
-
Active internal bleeding, or history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month (30 days)
-
A medical diagnosis that requires continuous use of aspirin, clopidogrel, ticagrelor, or tirofiban during the study drug infusion
-
New parenchymal hemorrhage or new infarction larger than 15 cubic centimeters (cc) in volume by CT
-
Thrombolytic therapy within 24 hours prior to enrollment (alteplase, tenecteplase, or urokinase)
-
Previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial-venous malformation
-
Thrombocytopenia (platelet count <100,000/microliter (µL) assuming clumping is ruled out
-
Allergy or intolerance to tirofiban
-
Pregnant or lactating
-
Chronic kidney disease with creatinine clearance (CrCl ≤ 30 milliliters per minute [ml/min]) or acute kidney injury (AKI) at study screening. AKI is defined as:
i) Increase in serum creatinine by 0.3 milligrams per deciliter (mg/dL) or more (26.5 micromoles per liter [μmol/L] or more) within 48 hour period; OR ii) Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 day period; OR iii) Urine volume less than 0.5 ml/kg/hour for at least 6 hours
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Tirofiban
Continuous IV infusion of tirofiban for 1, 3, 5, or 7 days post-endovascular coiling. |
IV infusion at 0.10 microgram/kilogram/minute (mcg/kg/min) for 1 day, 3 days, 5 days, or 7 days according to the dose escalation procedure.
Ostatní jména:
|
|
Komparátor placeba: Placebo
Continuous IV infusion of saline placebo for 1, 3, 5, or 7 days post-endovascular coiling. |
IV infusion at the same infusion duration as the study drug; same adjustments
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Tirofiban dosage-limiting toxicity (DLT)
Časové okno: Within 14 days post-randomization
|
Presence of any of the following: any intracranial hemorrhage, major extracranial hemorrhage (defined as clinically overt bleeding leading to death; OR clinically overt bleeding causing a reduction in hemoglobin of ≥2g/dl; OR clinically overt bleeding necessitating transfusion of ≥2 units of packed red cells or whole blood; OR clinically overt bleeding in a critical area or organ other than the intracranial compartment (including intraspinal, intraocular, pericardial, intra-articular, retroperitoneal, intramuscular [with compartment syndrome])), thrombocytopenia, or serious adverse event (SAE) due to tirofiban. |
Within 14 days post-randomization
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Farmacokinetické parametry - celková clearance (Cltot)
Časové okno: Až 7 hodin po vysazení léku
|
Až 7 hodin po vysazení léku
|
|
|
Farmakokinetické parametry - Distribuční objem (Vd)
Časové okno: Až 7 hodin po vysazení léku
|
Až 7 hodin po vysazení léku
|
|
|
Pharmacokinetic parameters - Maximum (peak) plasma concentration (Cmax)
Časové okno: Up to 7 hours after drug discontinuation
|
Highest concentration of tirofiban in the blood after a dose is administered |
Up to 7 hours after drug discontinuation
|
|
Pharmacokinetic parameters - Minimum (trough) plasma concentration (Cmin)
Časové okno: Up to 7 hours after drug discontinuation
|
Lowest observed concentration of tirofiban in the blood after a dose is administered |
Up to 7 hours after drug discontinuation
|
|
Pharmacokinetic parameters - Average Plasma Concentration (Cavg)
Časové okno: Up to 7 hours after drug discontinuation
|
Average tirofiban concentration in the blood at steady state |
Up to 7 hours after drug discontinuation
|
|
Pharmacokinetic parameters - Area Under the Concentration (AUC)Time Curve
Časové okno: Up to 7 hours after drug discontinuation
|
Area under the curve from time 0 extrapolated to infinite time |
Up to 7 hours after drug discontinuation
|
|
Pharmacodynamic parameters - adenosine diphosphate (ADP)
Časové okno: Baseline, 2, 6, and every 24 hours and at drug cessation
|
The percent inhibition of ADP-induced platelet aggregation |
Baseline, 2, 6, and every 24 hours and at drug cessation
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Delayed cerebral ischemia (DCI) or death without DCI
Časové okno: Within 14 days post-randomization
|
This is the primary exploratory efficacy outcome, which is a composite binary outcome. DCI is defined as any of the following: a. Focal neurological impairment, b. decrease of at least 2 points on the Glasgow coma scale and/or c. cerebral infarction present on final CT or MRI, which was not present on a CT or MRI between 24-48 hours post-endovascular therapy and not attributable to other causes. |
Within 14 days post-randomization
|
|
Cerebral vasospasm
Časové okno: Within 14 days post-randomization or until discharge from the index admission, which occurred later
|
Cerebral vasospasm requires confirmation of vasospasm on either CTA or DSA confirming mild vasospasm (decrease in vessel diameter by ≤25% of normal artery diameter), moderate vasospasm (decrease in vessel diameter by >25 to ≤50% of normal diameter but cerebral vasospasm), or severe vasospasm (decrease in vessel diameter by >50% of normal vessel diameter) |
Within 14 days post-randomization or until discharge from the index admission, which occurred later
|
|
Mortality
Časové okno: 3 and 6 months post-randomization
|
Death of any cause |
3 and 6 months post-randomization
|
|
Total number of days in the ICU for the index admission
Časové okno: Up to 6 months post-randomization
|
Total number of days from ICU admission to ICU discharge during the index hospitalization |
Up to 6 months post-randomization
|
|
Total hospital stay length for the index admission
Časové okno: Up to 6 months post-randomization
|
Total number of days from admission to discharge during the index admission |
Up to 6 months post-randomization
|
|
Modified Rankin Scale (mRS)
Časové okno: 3 and 6 months post-randomization
|
It is a clinician-reported measure of global disability, widely applied for evaluating stroke patient outcomes and as an endpoint in randomized clinical trials. It is a single-item 7-point scale with a range of 0 (no symptoms at all) to 6 (death), with higher scores indicating greater disability. The elements of the mRS are as follows: (1) no symptoms at all; (2) no significant disability, but there may be slight symptoms such as weakness or numbness; (3) slight disability, but able to carry out daily activities independently; (4) moderate disability, requiring some help with daily activities; (5) moderately severe disability, requiring assistance with most daily activities; (6) severe disability, bedridden and requiring constant nursing care; and (7) death. |
3 and 6 months post-randomization
|
|
Return to work
Časové okno: 3 and 6 months post-randomization
|
Returned to prior level of responsibilities at work |
3 and 6 months post-randomization
|
|
Lawton Instrumental Activities of Daily Living (Lawton IADL)
Časové okno: 3 and 6 months post-randomization
|
It is an instrument to assess independent living skills among older adults, and can be used in community or hospital settings. There are 8 domains of function measured with the scale: (1) using the telephone; (2) shopping; (3) preparing food; (4) housekeeping; (5) doing laundry; (6) using transportation; (7) handling medications; (8) handling finances. Women are scored on all 8 areas of function; historically, for men, the areas of food preparation, housekeeping, and laundering are excluded. Individuals are scored according to their highest level of functioning in that category. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men. |
3 and 6 months post-randomization
|
|
Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS)
Časové okno: 3 and 6 months post-randomization
|
It is a 6-item scale to evaluate the overall satisfaction with facets of life relevant to people with traumatic brain injury. The area covered by the questionnaire includes physical condition, cognition, emotions, function in daily life, personal and social life, and current situation and future prospects. Responses to each item were scored 1 ('Not at all') to 5 ('Very'), and the sum of all items was converted arithmetically to a percentage scale, with 0 representing the lowest possible (health-related quality of life (HRQoL) on the questionnaire and 100 the best possible HRQoL. |
3 and 6 months post-randomization
|
|
Glasgow Outcome Scale-Extended (GOS-E)
Časové okno: 3 and 6 months post-randomization
|
It is used to assess global outcomes in persons with brain injury, by categorizing global function using an 8-point ordinal scale that focuses on disability and functioning in daily life. The scales are: 1. Dead, 2. Vegetative State, 3. Lower Severe Disability (SD), 4. Upper SD, 5. Lower Moderate Disability (MD), 6. Upper MD, 7. Lower Good Recovery (GR), 8. Upper GR |
3 and 6 months post-randomization
|
|
PROMIS-29+2
Časové okno: 3 and 6 months post-randomization
|
The Patient-Reported Outcomes Measurement Information System® (PROMIS) is a flexible set of tools designed to measure self-reported physical, mental, and social health and wellbeing. PROMIS-29+2 is a collection of 4-item Likert-item short forms assessing the following domains:
Norm-based scores will be calculated for each domain on the PROMIS measures, so that a score of 50 represents the mean or average of the reference population. A score of 60 means that the person is one standard deviation above the reference population (standard deviation = 10). For PROMIS measures, higher scores equal more of the concept being measured (e.g., more Fatigue, more Physical Function). |
3 and 6 months post-randomization
|
|
Montreal Cognitive Assessment (MoCA)
Časové okno: 3 and 6 months post-randomization
|
It is a 30-point test to assess people for dementia. The MoCA evaluates different types of cognitive abilities, including orientation, short-term memory / delayed recall, executive function / visuospatial ability, language ability, abstraction, animal naming, attention, and clock-drawing. Scores range from 0 to 30, with a score of 26 or higher considered normal. |
3 and 6 months post-randomization
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Emad Hasan, MD, Duke University
- Vrchní vyšetřovatel: Brian Mac Grory, MD, Duke University
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Cerebrovaskulární poruchy
- Onemocnění mozku
- Onemocnění centrálního nervového systému
- Nemoci nervového systému
- Cévní onemocnění
- Kardiovaskulární choroby
- Patologické procesy
- Krvácení
- Intrakraniální krvácení
- Patologické stavy, příznaky a symptomy
- Subarachnoidální krvácení
- Aminokyseliny, peptidy a proteiny
- Farmaceutické přípravky
- Aminokyseliny
- Krystaloidní roztoky
- Izotonická řešení
- Řešení
- Aminokyseliny, aromatické
- Aminokyseliny, cyklické
- Tyrosin
- Tirofiban
- Solný roztok
Další identifikační čísla studie
- Pro00119469
- UG3NS138219 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .